From GlobeNewswire: 2025-05-06 08:00:00

Cogent Biosciences announced three key data readouts in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM in the second half of the year, and PEAK in GIST by year-end. The company ended Q1 2025 with $245.7 million in cash, sufficient to fund operations into late 2026.

In Q1 2025, Cogent Biosciences reported a productive quarter with expanded clinical results for bezuclastinib in NonAdvSM patients, showing a 65% improvement in Total Symptom Score. The company also presented updated preclinical data at the AACR annual meeting for multiple candidates.

Upcoming milestones include top-line results from SUMMIT in July 2025, APEX in the second half of 2025, and PEAK by the end of 2025. These trials focus on different conditions such as NonAdvSM, AdvSM, and GIST, respectively.

In Q1 2025, Cogent Biosciences had $245.7 million in cash and cash equivalents, enough to fund operations into late 2026. Research and development expenses were $63.0 million, and general and administrative expenses were $11.9 million. The net loss for the quarter was $72.0 million.

Cogent Biosciences is a biotechnology company developing precision therapies for genetically defined diseases, with a focus on bezuclastinib for systemic mastocytosis and GIST. The company also has ongoing studies in other targeted therapies. For more information, visit their website. Contact Senior Director of Investor Relations, Christi Waarich, at [email protected] or 617-830-1653.



Read more at GlobeNewswire:: Cogent Biosciences Reports First Quarter 2025 Financial